Fresenius SE & Co KGaA

Fresenius is a health care group providing products and services for dialysis, hospitals and outpatient medical care. Co. operates four business segments: Fresenius Medical Care; Fresenius Kabi; Fresenius Helios; and Fresenius Vamed. Fresenius Medical Care provides dialysis care and dialysis products for patients with chronic kidney failure. Fresenius Kabi is engaged in the provision of generic drugs, infusion therapies, clinical nutrition products, related medical devices and transfusion technology. Fresenius Vamed manages projects and provides services for hospitals and other health care facilities. Fresenius Helios is a private hospital operator which only operates in Germany.
  • Ticker578560
  • ISINDE0005785604
  • SectorHealth Care Equipment & Services
  • CountryGermany

Analysts

Julie Utterback

Morningstar | Affirming Our Narrow-Moat Ratings for Baxter and Fresenius SE; Raising Fair Value Estimates

After taking a fresh look at dialysis and injectable therapy-focused Baxter and Fresenius SE, we are maintaining our narrow moat and stable trend ratings for both firms. We are also raising our fair value estimates, as we account for cash flows generated since previous updates and adjustments to underlying projections. For Baxter, we are raising our fair value estimate to $69 per share, or about 21 times our updated 2019 earnings, from $63 per share previously. For Fresenius, we are increasing our fair value estimate for its local shares to EUR 60 per share, or 18 times our updated 2019 earnin...

Julie Utterback

Affirming Our Narrow-Moat Ratings for Baxter and Fresenius SE; Raising Fair Value Estimates

After taking a fresh look at dialysis and injectable therapy-focused Baxter and Fresenius SE, we are maintaining our narrow moat and stable trend ratings for both firms. We are also raising our fair value estimates, as we account for cash flows generated since previous updates and adjustments to underlying projections. For Baxter, we are raising our fair value estimate to $69 per share, or about 21 times our updated 2019 earnings, from $63 per share previously. For Fresenius, we are increasing o...

Julie Utterback

Morningstar | Fresenius SE Continues to Vertically Integrate in Healthcare Services and Injectable Therapies

Fresenius SE’s prowess in dialysis and injectable therapies has created opportunities to vertically integrate into several medical service and technology businesses by organic and inorganic means. Through its partial ownership of Fresenius Medical Care, the company seeks to benefit from that unique entity's position as the top dialysis service and product provider. In the U.S., this segment operates a convenient network of dialysis clinics at a similar scale as key peer DaVita, serving about three fourths of the U.S. dialysis outpatient population between the two firms. Fresenius has establish...

Julie Utterback

Fresenius SE Continues to Vertically Integrate in Healthcare Services and Injectable Therapies

We continue to have Fresenius SE under review as we transfer coverage to a new analyst. We expect to publish a new fair value estimate later in May....

Michael Waterhouse

Morningstar | Fresenius Under Review

We continue to have Fresenius SE under review as we transfer coverage to a new analyst. We expect to publish a new fair value estimate later in May.

Fresenius SE & Co. KGaA: Update to Credit Analysis

Update to credit analysis following full year 2017 results, the termination of the Akorn acquisition ($4.3 billion) and FMC's divestment of Sound ($2.15 billion)

Fresenius SE & Co. KGaA: Fresenius SE could save $6.9 billion, a credit positive

The sale of Sound for $2.15 billion and termination of the $4.75 billion Akorn acquisition will strengthen Fresenius SE's credit metrics.

Fresenius SE & Co. KGaA (FSE): FAQ about FSE's financial policy in the context of recent acquisitions

CORPORATES ISSUER IN-DEPTH 19 October 2017 RATINGS Fresenius SE & Co. KGaA Long term Issuer rating Baa3 Senior Unsecured rating Baa3 Backed Senior Unsecured MTN (P)Baa3 Outlook Stable Source: Moody's Investors Service KEY METRICS: Fresenius SE & Co. KGaA 2016 2015 2014 Revenue ($ billion) $32.2

Julie Utterback

Morningstar | Affirming Our Narrow-Moat Ratings for Baxter and Fresenius SE; Raising Fair Value Estimates

After taking a fresh look at dialysis and injectable therapy-focused Baxter and Fresenius SE, we are maintaining our narrow moat and stable trend ratings for both firms. We are also raising our fair value estimates, as we account for cash flows generated since previous updates and adjustments to underlying projections. For Baxter, we are raising our fair value estimate to $69 per share, or about 21 times our updated 2019 earnings, from $63 per share previously. For Fresenius, we are increasing our fair value estimate for its local shares to EUR 60 per share, or 18 times our updated 2019 earnin...

Julie Utterback

Affirming Our Narrow-Moat Ratings for Baxter and Fresenius SE; Raising Fair Value Estimates

After taking a fresh look at dialysis and injectable therapy-focused Baxter and Fresenius SE, we are maintaining our narrow moat and stable trend ratings for both firms. We are also raising our fair value estimates, as we account for cash flows generated since previous updates and adjustments to underlying projections. For Baxter, we are raising our fair value estimate to $69 per share, or about 21 times our updated 2019 earnings, from $63 per share previously. For Fresenius, we are increasing o...

Julie Utterback

Morningstar | Fresenius SE Continues to Vertically Integrate in Healthcare Services and Injectable Therapies

Fresenius SE’s prowess in dialysis and injectable therapies has created opportunities to vertically integrate into several medical service and technology businesses by organic and inorganic means. Through its partial ownership of Fresenius Medical Care, the company seeks to benefit from that unique entity's position as the top dialysis service and product provider. In the U.S., this segment operates a convenient network of dialysis clinics at a similar scale as key peer DaVita, serving about three fourths of the U.S. dialysis outpatient population between the two firms. Fresenius has establish...

Julie Utterback

Fresenius SE Continues to Vertically Integrate in Healthcare Services and Injectable Therapies

We continue to have Fresenius SE under review as we transfer coverage to a new analyst. We expect to publish a new fair value estimate later in May....

Michael Waterhouse

Morningstar | Fresenius Under Review

We continue to have Fresenius SE under review as we transfer coverage to a new analyst. We expect to publish a new fair value estimate later in May.

1 director bought

A director at Fresenius Se & Co Kgaa bought 2,000 shares at 50.957EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names...

Ahmed Ben Salem ...
  • Jean-Baptiste Rouphael
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Valentin Pernet
  • Veysel Taze
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 12/14/2018

...

Ahmed Ben Salem ...
  • Jean-Baptiste Rouphael
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Valentin Pernet
  • Veysel Taze
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 14/12/2018

...

Ahmed Ben Salem ...
  • Benoit Valleaux
  • Bruno Cavalier
  • Igor Kim
  • Jean Sassus
  • Jerôme Bodin
  • Johanna Jourdain
  • Matthias Desmarais
  • Steven Gould

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 12/10/2018

...

Ahmed Ben Salem ...
  • Benoit Valleaux
  • Bruno Cavalier
  • Igor Kim
  • Jean Sassus
  • Jerôme Bodin
  • Johanna Jourdain
  • Matthias Desmarais
  • Steven Gould

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 10/12/2018

...

Ahmed Ben Salem ...
  • Alex Koagne
  • Alfred Glaser
  • Anis Zgaya
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Igor Kim, CFA
  • Jean Sassus
  • Louis Boujard, CFA
  • Oussema Denguir
  • Philippe Ourpatian
  • Pierre Corby
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri
  • Sven Edelfelt
  • Veysel Taze
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 08/01/2018

...

Nurhayati Wan

Fresenius SE & Co. KGaA

Nurhayati Wan

Fresenius SE & Co. KGaA

Nurhayati Wan

Fresenius SE & Co. KGaA

Nurhayati Wan

Fresenius SE & Co. KGaA

Nurhayati Wan

Fresenius SE & Co. KGaA

Eric Le Berrigaud ...
  • Gary Waanders
  • Hugo Solvet
  • Jean-Jacques Le Fur

Healthcare: Five picks in healthcare in Q4 with Fresenius, Galapagos, Genmab, Novartis and Sanofi

Healthcare Five picks in healthcare in Q4 with Fresenius, Galapagos, Genmab, Novartis and Sanofi

Expert Corporate Governance Service (ECGS)

Fresenius SE & Co. KGaA - AGM 17 May 2019

Item 1: Unlike at German stock corporations, shareholders of a KGaA are legally required to vote on the annual accounts. Item 5a: KPMG has audited the Company since the financial year 1981 which exceeds our maximum acceptable term of office. We welcome however that the Company has announced to change the audit firm as of financial year 2020, see item 5b of the agenda, and therefore exceptionally recommend to support the reappointment of KPMG.

Fresenius SE – Proxinvest Corporate Governance Rating ® : D

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Jérôme VINERIER

Analyse court terme - FRESENIUS SE & CO KGAA : Le mouvement se poursuit.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 55,10 €, puis 51,43 €. Le franchissement de 64,80 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Short term view - FRESENIUS SE & CO KGAA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €55.10, then €51.43. Passing €64.80 would question the continuation of the fall.

Jérôme VINERIER

Analyse court terme - FRESENIUS SE & CO KGAA : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 58,90 €, puis 55,10 €. Le franchissement de 70,90 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Short term view - FRESENIUS SE & CO KGAA : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €58.90, then €55.10. Passing €70.90 would question the continuation of the fall.

Valérie GASTALDY

Medium term view - FRESENIUS SE & CO KGAA : The trend is bearish.

The trend is bearish. The movement goes on. The next target is at €59.50, then €51.24. Passing €71.80 would question the continuation of the fall.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch